logo
 
India's indigenous coronavirus vaccine, Covaxin, has shown to generate robust immune responses in its first phase clinical trials.

A detailed immunogenicity response of the first phase trials of the vaccine has been declared by the manufacturers. Covaxin, jointly developed by Hyderabad-based Bharat Biotech and ICMR has been found to be safe generating no serious adverse effects in people of all dose groups as per the results of the first phase clinical trials. ICMR has informed that the vaccine can be stored at 2 and 8-degree centigrade temperatures which also makes it compatible with the National Immunization plan. 
 
Covaxin is one of the three coronavirus vaccine candidates being considered for emergency use authorization in India by the Drug regulator. It is currently in its third and last phase of clinical trials with nearly 26 thousand volunteers in the age group of 18 and 55. 

No Comments For This Post, Be first to write a Comment.
Leave a Comment
Name:
Email:
Comment:
Enter the code shown:


Can't read the image? click here to refresh

Todays Epaper

Latest Urdu News

Is it safe to take Covid vaccine?

Yes
No
Can't Say